A B S T R A C T We have developed a method for the direct analysis of a hypoxanthine-guanine phosphoribosyltransferase (HPRT) allele associated with a deficiency of enzyme activity and an early onset of gout. The functionally abnormal enzyme coded for by this mutant allele (HPRTToronto) differs from the normal enzyme by an arginine-to-glycine substitution at position 50. A single base change in the codon for arginine 50 can explain this substitution. Direct analysis of this point mutation is based on the observation that it abolishes a Taq I recognition site in HPRT DNA. As predicted, DNA from individuals with the HPRTToro,,to allele exhibited an abnormal restriction pattern when digested with Taq I and probed with HPRT complimentary DNA: a normal 2.0-kb fragment is replaced by a 4.0-kb fragment. The 4.0/2.0-kb restriction fragment variation was used to detect the HPRTToronto allele in a heterozygote that was otherwise normal with respect to the classical techniques used to diagnose heterozygosity in HPRT deficiency.
INTRODUCTION
Many inherited diseases are caused by defects at single genetic loci. These disorders are usually diagnosed by direct assay of the mutant gene product or by biochemical analysis of the metabolic aberrations that result from the primary defect in protein function. A more recent approach to diagnosis, which has been developed for several alleles at the ,B-globin locus, involves detection of the mutation of interest with spe-cific DNA probes. Prenatal diagnosis of sickle cell anemia by direct analysis of DNA in amniotic cells is the most widely celebrated example of this elegant technology. Several approaches have now been described (reviewed in reference 1). Segregation analysis of restriction fragment length polymorphisms linked to the ,#-globin gene has been used to identify the sickle cell allele in certain families. Restriction enzymes whose recognition sequences are altered by the sickle cell mutation can be used to directly identify the mutant gene from small quantities of DNA. More recently, Conner et al. (2) utilized synthetic oligonucleotides to specifically probe for the sickle cell mutation.
Several inborn errors of metabolism, including a deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT),' should also be amenable to detection at the level of genomic DNA. HPRT deficiency is an X-linked recessive disorder that can lead to an early onset of gout (3) or, in its most severe form, the Lesch-Nyhan syndrome (4) . DNA probes for the human HPRT gene are now available (5, 6 HPRTToronto is a structural variant isolated from a patient with a partial deficiency of enzyme activity who presented with gout and uric acid nephrolithiasis at an early age (7, 8) . This mutant enzyme differs from normal by an arginine-to-glycine amino acid substitution at position 50 (9) . The deficiency of HPRT activity in this patient is caused by decreased levels of enzyme protein (7, 8) as well as increased inhibition of enzyme activity by the product guanosine monophosphate (GMP) (9 
METHODS
Enzymeassays. Hemolysateswerepreparedfromfreshly drawn blood as described (7). Previously described radiochemical techniques were used to assay HPRT (7) and adenine phosphoribosyltransferase (APRT) (10) .
Patients and DNA isolation. The clinical, genetic, and biochemical features of the P. family have been described (11) (12) . A partial pedigree of this kindred is shown in Fig.  1 High-molecular-weight DNA was isolated from leukocytes or, when possible, cultured lymphoblasts as described (6) . cDNA probe for human HPRT. The isolation and characterization of HPRT cDNA from a human fetal liver cDNA library has been described (6) . The recombinant used in this study, pHPT30, contains a 972-kb cDNA insert in the Pst I site of the plasmid vector pKT218. This HPRT cDNA contains 80 base pairs (bp) of 5'-noncoding sequence, the entire translated region, and -250 bp of 3'-noncoding sequence. The cDNA was excised from the plasmid by digestion with Pst I and was isolated from 1% low-melting agarose gels ( 
RESULTS
Activity of HPRT and APRT in erythrocytes from the P. family. Detection of the HPRTTOTOntO mutation with the restriction enzyme Taq I. Deficiency of HPRT activity in the P. family is caused by a single amino acid substitution, arginine to glycine, at position 50 of the enzyme (9) . An analysis of the nucleotide sequence of HPRT CDNA (5) indicated that the proposed substitution can be explained by a single nucleotide change in the codon for arginine-50. Furthermore, we predict that this point mutation would obliterate a recognition site for the endonuclease Taq I (Fig. 2) .
Taq I digests of DNA isolated from several normal male subjects were analyzed by the method of Southern and were probed with near full-length HPRT cDNA (Fig. 3, lanes B and C) . This cDNA probe clearly hybridized to restriction fragments of 4.6, 3.7, 2.0, 1.5, 1.1, and 0.7 kb in length. Fainter bands were also consistently detected at 16.0 and 0.5 kb. Previous studies have identified autosomal sequences that are recognized by the HPRT cDNA (6) . DNA A large number of unrelated subjects were screened for variation in Taq I restriction fragments. These experiments were performed on a microscale to conserve time and resources. A total of 108 individuals have been tested without detectable variation in Taq I restriction fragment lengths (data not shown). This indicates that the 4.0/2.0-kb restriction fragment length variation detected in the P. family is probably not a polymorphism.
DISCUSSION
Direct identification of mutant genes by hybridization to DNA probes has been used in the diagnosis of several genetic disorders including certain hemoglobinopathies and thalassemia syndromes (reviewed in reference 1) and more recently a form of diabetes mellitus caused by a mutant insulin (14) . We describe in this report a sensitive assay for a mutant allele of HPRT that codes for a functionally abnormal enzyme (HPRTToronto) and is associated with a deficiency of enzyme activity and an early onset of a severe form of gout.
The assay for this mutation is based on the observation that it abolishes a Taq I restriction endonuclease recognition site in HPRT DNA. Southern blot analysis of DNA digested with Taq I and probed with HPRT cDNA provided a direct and sensitive method for detecting the HPRTTo,onto allele. Several important features of the Taq I assay are worth mentioning. The successful demonstration of Taq I restriction fragment length variation in this patient provided independent confirmation of the arginine-to-glycine substitution at position 50, previously identified by protein sequencing (9) . In addition, due to the ease and sensitivity of this assay, it will now be possible to screen rapidly a large population of gouty individuals for the same mutation. Finally, as described below, the Taq I assay provided a direct approach for detection of subjects heterozygous for this allele.
Previously described methods for detecting heterozygotes for a deficiency of HPRT are indirect and fraught with difficulties. Random inactivation of the X chromosome in HPRT-deficient heterozygotes produces cells with either normal or diminished HPRT activity. One approach to heterozygote detection is based on the demonstration of this mixed population of cells in possible carriers. Mosaicism with respect to HPRT activity can be demonstrated in cultured fibroblasts by measuring the incorporation of radiolabeled hypoxanthine into nucleic acids (15) or the relative cellular sensitivity to toxic purine analogues (16) . Mosaicism can also be demonstrated by analysis of hair roots (17) . Although these techniques have been successful in detecting heterozygotes for the Lesch-Nyhan syndrome, they lack the sensitivity necessary to differentiate normal cells from cells with a partial deficiency of HPRT, and therefore have proven to be inadequate in the diagnosis of some patients that are hemizygous or heterozygous for the partial enzyme defect. Another indirect approach to heterozygote detection, which also has had limited application, is the assay of HPRT have noted similar intrafamily variation in HPRT and APRT activity of obligate HPRT-deficient heterozygotes (32). Direct analysis of the HPRT structural genes in these family members by the Taq I assay provided direct and unequivocal evidence for the genotype of the propositus, the heterozygotes (mother and daughter), and the unaffected brother.
Detection of mutant HPRT alleles by DNA hybridization provides an alternative approach for prenatal diagnosis of the more severe form of HPRT deficiency, the Lesch-Nyhan syndrome. Nussbaum et al. (6) recently described the use of silent restriction fragment length polymorphisms as markers for the indirect identification of deleterious HPRT alleles. We have illustrated in this report a direct approach for identifying mutations that affect restriction endonuclease recognition sites. A powerful technique, which may have application in the detection of other defined mutations at the HPRT locus, is the differential hybridization of complementary oligonucleotide probes. An important feature of direct gene analysis, as it relates to prenatal diagnosis, is the sensitivity of the technique. In contrast to the conventional methods of prenatal diagnosis of HPRT deficiency, which require propagation of amniotic cells in vitro for several weeks, analysis of mutant alleles by DNA hybridization can be performed directly on cells obtained from 5-10 ml of amniotic fluid. Taq I analysis of DNA isolated from amniotic fluid of two normal fetuses has in fact been done.4
In conclusion, we have developed a DNA hybridization assay for detecting the HPRTToronto mutation from small quantities of genomic DNA. This provided independent confirmation of the mutation in this variant allele, previously defined by protein sequence analysis. Finally, we used this assay to detect a heterozygote that was otherwise normal with respect to the classical techniques used to diagnose heterozygosity in HPRT deficiency.
